These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6534118)

  • 21. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
    Kerins DM
    Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of fluosol-DA on induction of inhalation anesthetics.
    Chilcoat RT; Gerson JI; Allen FB; Mapleson WW
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):557-63. PubMed ID: 3179489
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of Fluosol-DA on radioimmunoassay results.
    Hammarstrom M; Mullins R; Sgoutas D
    Clin Chem; 1983 Jul; 29(7):1418-21. PubMed ID: 6861348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with Fluosol-DA (20%) in the United States.
    Tremper KK; Levine EM; Waxman K
    Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
    [No Abstract]   [Full Text] [Related]  

  • 25. Whole body oxygenation using intraperitoneal perfusion of fluorocarbons.
    Faithfull NS; Klein J; van der Zee HT; Salt PJ
    Br J Anaesth; 1984 Aug; 56(8):867-72. PubMed ID: 6430312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure to determine heparin concentrations in plasma containing Fluosol-DA using an analytical kit.
    Shrewsbury RP; White LG
    Clin Chim Acta; 1989 Feb; 179(3):347-8. PubMed ID: 2714008
    [No Abstract]   [Full Text] [Related]  

  • 27. Maternal and fetal effects of exchange transfusion with a red blood cell substitute.
    Cefalo RC; Seeds JW; Proctor HJ; Baker VV
    Am J Obstet Gynecol; 1984 Apr; 148(7):859-67. PubMed ID: 6711627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic monitoring during continuous warm- and cold-blood cardioplegia by means of myocardial tissue pH and PO2.
    Carrier M; Trudelle S; Khalil A; Pelletier LC
    Can J Surg; 1998 Apr; 41(2):142-8. PubMed ID: 9575998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal circulation with perfluorochemicals (Fluosol-DA).
    Hoshino S; Iwaya F; Igari T; Kanno M; Honda K
    J Cardiovasc Surg (Torino); 1982; 23(6):463-9. PubMed ID: 7153234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
    Police AM; Waxman K; Tominaga G
    Crit Care Med; 1985 Feb; 13(2):96-8. PubMed ID: 3967511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of synthetic blood and crystalloid cardioplegic solutions on coronary endothelium: an experimental scanning electron microscope study.
    Harjula A; Mattila S; Myllärniemi H; Mattila I; Mattila P; Salmenperä M; Merikallio E
    J Surg Res; 1985 Nov; 39(5):405-12. PubMed ID: 4058003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superiority of perfluorocarbon cardioplegia over blood or crystalloid cardioplegia.
    Kanter KR; Jaffin JH; Ehrlichman RJ; Flaherty JT; Gott VL; Gardner TJ
    Circulation; 1981 Aug; 64(2 Pt 2):II75-80. PubMed ID: 7249332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An experimental study on fluorocarbons as blood substitutes.
    Motta G; Ratto GB; De Barbieri A; Tomellini M; Rovatti M; Sacco A; Castagnola M
    Ital J Surg Sci; 1983; 13(2):89-93. PubMed ID: 6629736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Fluosol-DA (20%) on skin flap survival in rats.
    Ramasastry SS; Waterman P; Angel MF; Futrell JW
    Ann Plast Surg; 1985 Nov; 15(5):436-42. PubMed ID: 4083744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of perfluorocarbon blood substitutes determined by sedimentation field-flow fractionation.
    Yang FS; Caldwell KD; Giddings JC; Astle L
    Anal Biochem; 1984 May; 138(2):488-94. PubMed ID: 6742424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA committee questions Fluosol efficacy; US approval not imminent.
    Marwick C
    JAMA; 1983 Nov; 250(19):2585-6. PubMed ID: 6632147
    [No Abstract]   [Full Text] [Related]  

  • 37. Improved myocardial protection with perfluorocarbon cardioplegia.
    Gardner TJ; Flaherty JT; Kanter KR; Magovern GJ
    Prog Clin Biol Res; 1983; 122():405-17. PubMed ID: 6878379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of different oxygen concentrations during hemodilution with Fluosol or LMW-Dextran in rabbits.
    Beisbarth H; Madjidi A; Frey R
    Prog Clin Biol Res; 1983; 122():373-80. PubMed ID: 6192450
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluorocarbons and the microcirculation.
    Faithfull NS; Fennema M; Van Alphen WA; Smith AR; Erdmann W; Essed CE; Kok A; Lapin R
    Acta Anaesthesiol Belg; 1984; 35 Suppl():69-78. PubMed ID: 6516761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of varying extents of Fluosol-DA or normal saline haemodilution on the dose dependent kinetics of phenytoin in the rat.
    Shrewsbury RP; Oliver SR; Lewis LM; Anderson WT; White LG
    J Pharm Pharmacol; 1989 Aug; 41(8):582-4. PubMed ID: 2571710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.